UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

	•			,
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/698,323	10/27/2000	Jeffrey M. Isner	47624-DIV (1417)	6299
21874 7590 07/12/2007 EDWARDS ANGELL PALMER & DODGE LLP P.O. BOX 55874			EXAMINER	
			NGUYEN, QUANG	
BOSTON, MA	02205		ART UNIT	PAPER NUMBER
•			1633	
		•	MAIL DATE	DELIVERY MODE
•			07/12/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
	09/698,323	ISNER ET AL.			
Office Action Summary	Examiner	Art Unit			
	Quang Nguyen, Ph.D.	1633			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the o	correspondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (8) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period was preply reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tir will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	N. mely filed the mailing date of this communication. ED (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on <u>06 Ai</u> 2a) This action is FINAL . 2b) This 3) Since this application is in condition for allowar closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro				
Disposition of Claims					
4) ☐ Claim(s) 50,52,55-63,65-68,70,72-78 and 82-8 4a) Of the above claim(s) is/are withdray 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) 50, 52, 55-63, 65-68, 70, 72-78, 82-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-	vn from consideration.				
Application Papers					
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) accomplicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Example 11.	epted or b) objected to by the drawing(s) be held in abeyance. Se tion is required if the drawing(s) is ob	ee 37 CFR 1.85(a). pjected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
Attachment(s) 1) Notice of References Cited (PTO-892)	4) 🔲 Interview Summar				
Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	Paper No(s)/Mail D 5) Notice of Informal 6) Other:				

Art Unit: 1633

DETAILED ACTION

Applicant's amendment filed on 4/6/07 was entered.

Amended claims 50, 52, 55-63, 65-68, 70, 72-78 and 82-84 are pending in the present application, and they are subjected to the following species restriction.

Species Election/Restrictions

This application contains claims directed to the following patentably distinct species:

- (a) A method for inducing formation of new blood vessels in a mammal having chronic or acute ischemia, comprising administering to the mammal <u>an effective amount</u> of VEGF and GM-CSF or an effective fragment thereof;
- (b) A method for inducing formation of new blood vessels in a mammal having chronic or acute ischemia, comprising administering to the mammal <u>an amount of GM-CSF sufficient to increase frequency of endothelial progenitor cells in the mammal;</u>

The species are independent or distinct because the above methods utilize different starting materials that have different specific components, and that they may have different properties one from the other. For this instance, the method of species (a) utilizes a composition comprising an effective amount of both VEGF and GM-CSF or its fragment; whereas the method of species (b) does not require the presence of VEGF in the administered composition.

Application/Control Number: 09/698,323

Art Unit: 1633

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Quang Nguyen, Ph.D., whose telephone number is (571) 272-0776.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's SPE, Joseph T. Woitach, Ph.D., may be reached at (571) 272-0739.

To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Group Art Unit 1633; Central Fax No. (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your

Art Unit: 1633

application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

QUANG NGU EN RH.D.
PRIMARY EXAMINED